PDUFA Negotiations Would Add Patient, Consumer Reps Under House Bill
Executive Summary
The role of drug manufacturers in negotiating how FDA spends prescription drug user fees would be diminished under a draft user fee reauthorization bill prepared for markup in the House Energy and Commerce Committee's Health Subcommittee
You may also be interested in...
FDA Bill Passes; Congress Adds $225 Million To Industry User Fee Burden
Final FDA reform legislation that cleared Congress adds an additional $225 million to industry's user fee tab over five years, but limits penalties that FDA can assess to enforce its new authorities to mandate labeling changes and postmarket studies
FDA Bill Passes; Congress Adds $225 Million To Industry User Fee Burden
Final FDA reform legislation that cleared Congress adds an additional $225 million to industry's user fee tab over five years, but limits penalties that FDA can assess to enforce its new authorities to mandate labeling changes and postmarket studies
PhRMA’s Compromise Offer On Drug Safety Would “Clarify” FDA’s Powers
The Pharmaceutical Research and Manufacturers of America is proposing reforms to FDA's safety powers that would allow quicker regulatory actions, but not fundamentally alter the agency's authority